Literature DB >> 22526543

Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice.

K J Jackson1, J P McLaughlin, F I Carroll, M I Damaj.   

Abstract

RATIONALE: Several studies implicate stress as a risk factor for the development and maintenance of drug addictive behaviors and drug relapse. Kappa opioid receptor (KOR) antagonists have been shown to attenuate behavioral responses to stress and stress-induced reinstatement of cocaine and ethanol seeking and preference.
OBJECTIVES: In the current study, we determined whether the selective KOR antagonist, norbinaltorphimine (nor-BNI), would block stress-induced reinstatement of nicotine preference.
METHODS: Adult Institute of Cancer Research mice were conditioned with 0.5 mg/kg nicotine, injected subcutaneously (s.c.) for 3 days and tested in the nicotine-conditioned place preference (CPP) model. After 3 days extinction, nor-BNI (10 mg/kg, s.c.) was administered 16 h prior to a priming dose of nicotine (0.1 mg/kg, s.c.), and mice were tested in the CPP model for nicotine-induced reinstatement of CPP. A separate group of mice was subjected to a 2-day modified forced swim test (FST) paradigm to induce stress after 3 days extinction from CPP. Mice were given vehicle or nor-BNI (10 mg/kg, s.c.) 16 h prior to each FST session.
RESULTS: Nor-BNI pretreatment significantly attenuated stress-induced reinstatement of nicotine-CPP, but had no effect on nicotine-primed reinstatement.
CONCLUSIONS: Blockade of KORs by selective antagonists attenuates stress-induced reinstatement of nicotine-CPP. Overall, the kappa opioid system may serve as a therapeutic target for suppressing multiple signaling processes which contribute to maintenance of smoking, smoking relapse, and drug abuse in general.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526543      PMCID: PMC3821839          DOI: 10.1007/s00213-012-2716-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  The effects of smoking on the mood, cardiovascular and adrenergic reactivity of heavy and light smokers in a non-stressful environment.

Authors:  P M Cinciripini; C E Benedict; H Van Vunakis; R Mace; L Lapitsky; K Kitchens; E Nezami; H B Gjika
Journal:  Biol Psychol       Date:  1989-12       Impact factor: 3.251

2.  Increased desire to smoke during acute stress.

Authors:  K A Perkins; J E Grobe
Journal:  Br J Addict       Date:  1992-07

3.  Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking.

Authors:  R J West; P Hajek; M Belcher
Journal:  Psychol Med       Date:  1989-11       Impact factor: 7.723

4.  Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats.

Authors:  Patrick M Beardsley; James L Howard; Keith L Shelton; F Ivy Carroll
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

5.  Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Authors:  David Gonzales; Stephen I Rennard; Mitchell Nides; Cheryl Oncken; Salomon Azoulay; Clare B Billing; Eric J Watsky; Jason Gong; Kathryn E Williams; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

6.  Cigarette smoking during anxiety-provoking and monotonous tasks.

Authors:  J E Rose; S Ananda; M E Jarvik
Journal:  Addict Behav       Date:  1983       Impact factor: 3.913

7.  Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning.

Authors:  Jay P McLaughlin; Benjamin B Land; Shuang Li; John E Pintar; Charles Chavkin
Journal:  Neuropsychopharmacology       Date:  2006-04       Impact factor: 7.853

8.  Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men.

Authors:  Jack H Mendelson; Michelle B Sholar; Nathalie Goletiani; Arthur J Siegel; Nancy K Mello
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

9.  Smoking cessation in the workplace: evaluation of relapse factors.

Authors:  D M Daughton; D Roberts; K D Patil; S I Rennard
Journal:  Prev Med       Date:  1990-03       Impact factor: 4.018

10.  Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers.

Authors:  J N Wilkins; H E Carlson; H Van Vunakis; M A Hill; E Gritz; M E Jarvik
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

View more
  32 in total

1.  A Role for p38 Mitogen-activated Protein Kinase-mediated Threonine 30-dependent Norepinephrine Transporter Regulation in Cocaine Sensitization and Conditioned Place Preference.

Authors:  Padmanabhan Mannangatti; Kamalakkannan NarasimhaNaidu; Mohamad Imad Damaj; Sammanda Ramamoorthy; Lankupalle Damodara Jayanthi
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

2.  Variability in nicotine conditioned place preference and stress-induced reinstatement in mice: Effects of sex, initial chamber preference, and guanfacine.

Authors:  Angela M Lee; Cali A Calarco; Sherry A McKee; Yann S Mineur; Marina R Picciotto
Journal:  Genes Brain Behav       Date:  2019-08-13       Impact factor: 3.449

3.  Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.

Authors:  Kia J Jackson; Asti Jackson; F Ivy Carroll; M Imad Damaj
Journal:  Neuropharmacology       Date:  2015-06-01       Impact factor: 5.250

Review 4.  Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress.

Authors:  John R Mantsch; David A Baker; Douglas Funk; Anh D Lê; Yavin Shaham
Journal:  Neuropsychopharmacology       Date:  2015-05-15       Impact factor: 7.853

5.  MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats.

Authors:  Diana V Atigari; Rajendra Uprety; Gavril W Pasternak; Susruta Majumdar; Bronwyn M Kivell
Journal:  Neuropharmacology       Date:  2019-02-13       Impact factor: 5.250

6.  Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers.

Authors:  Daniel J O Roche; Lara A Ray; Megan M Yardley; Andrea C King
Journal:  Curr Addict Rep       Date:  2016-02-03

7.  Impaired Acquisition of Nicotine-Induced Conditioned Place Preference in Fatty Acid-Binding Protein 3 Null Mice.

Authors:  Wenbin Jia; Gofarana Wilar; Ichiro Kawahata; An Cheng; Kohji Fukunaga
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

8.  The long-term effects of stress and kappa opioid receptor activation on conditioned place aversion in male and female California mice.

Authors:  Abigail R Laman-Maharg; Tiffany Copeland; Evelyn Ordoñes Sanchez; Katharine L Campi; Brian C Trainor
Journal:  Behav Brain Res       Date:  2017-06-15       Impact factor: 3.332

9.  Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.

Authors:  Stephanie L Grella; Douglas Funk; Kathy Coen; Zhaoxia Li; A D Lê
Journal:  Behav Brain Res       Date:  2014-02-28       Impact factor: 3.332

10.  The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.

Authors:  Shainnel O Eans; Michelle L Ganno; Kate J Reilley; Kshitij A Patkar; Sanjeewa N Senadheera; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.